Form 4: Tenax Therapeutics Director Acquires 80,000 Stock Options

Tenax Therapeutics director June Sherie Almenoff acquired 80,000 stock options with an exercise price of $5.75, effective July 1, 2025, increasing her total beneficial ownership of derivative securities to 180,008 options.

Summary

• June Sherie Almenoff, a Director of TENAX THERAPEUTICS, INC. (TENX), reported changes in her beneficial ownership of company securities.
• On July 1, 2025, Ms. Almenoff acquired 80,000 stock options to purchase common stock.
• These newly acquired options have an exercise price of $5.75 per share, become exercisable on July 1, 2026, and expire on July 1, 2035.
• Following this transaction, Ms. Almenoff beneficially owns a total of 180,008 stock options.
• This total includes the newly acquired 80,000 options, plus previously held options: 4 options exercisable at $3,200 expiring June 10, 2031; 4 options exercisable at $992 expiring June 9, 2032; and 100,000 options exercisable at $5.94 expiring December 10, 2034.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director is generally viewed positively as it indicates confidence in the company's future and aligns the director's financial interests with those of shareholders.

Positives

• The acquisition of 80,000 stock options by a director can signal management's confidence in the company's future prospects and aligns their interests with those of shareholders.
• The options were acquired at a price of $0.00, indicating they were likely granted as compensation, which is a common practice to incentivize directors.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine disclosure of an insider transaction, common across all publicly traded companies, and does not directly relate to broader industry trends or competitive dynamics beyond the specific company's equity compensation practices.

Stakeholder Impact

• Shareholders: The acquisition of options by a director can be interpreted as a positive signal regarding the company's future performance, potentially influencing investor sentiment.
• Director (June Sherie Almenoff): Her equity stake in the company has increased, further aligning her financial incentives with the company's long-term success.

Next Steps

• The newly acquired stock options will become exercisable on July 1, 2026, at which point the director may choose to exercise them.

Key Dates

Keywords

TENAX THERAPEUTICS, TENX, Form 4, insider transaction, stock options, beneficial ownership, director compensation, equity compensation